[go: up one dir, main page]

ATE494387T1 - Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption - Google Patents

Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption

Info

Publication number
ATE494387T1
ATE494387T1 AT02806695T AT02806695T ATE494387T1 AT E494387 T1 ATE494387 T1 AT E494387T1 AT 02806695 T AT02806695 T AT 02806695T AT 02806695 T AT02806695 T AT 02806695T AT E494387 T1 ATE494387 T1 AT E494387T1
Authority
AT
Austria
Prior art keywords
epitope
substrate polypeptide
proteasome
liberation
contacting
Prior art date
Application number
AT02806695T
Other languages
English (en)
Inventor
John J L Simard
David C Diamond
Zhiyong Qui
Xiang-Dong Lei
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27662934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE494387(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mannkind Corp filed Critical Mannkind Corp
Application granted granted Critical
Publication of ATE494387T1 publication Critical patent/ATE494387T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT02806695T 2001-11-07 2002-11-07 Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption ATE494387T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33696801P 2001-11-07 2001-11-07
PCT/US2002/036098 WO2003063770A2 (en) 2001-11-07 2002-11-07 Expression vectors encoding epitopes of target-associated antigens and methods for their design

Publications (1)

Publication Number Publication Date
ATE494387T1 true ATE494387T1 (de) 2011-01-15

Family

ID=27662934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02806695T ATE494387T1 (de) 2001-11-07 2002-11-07 Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption

Country Status (12)

Country Link
US (3) US8637305B2 (de)
EP (2) EP2314712B1 (de)
CN (2) CN101024842A (de)
AT (1) ATE494387T1 (de)
AU (1) AU2008229722B2 (de)
CA (1) CA2469738A1 (de)
DE (1) DE60238864D1 (de)
DK (1) DK1453471T3 (de)
ES (1) ES2358642T3 (de)
HK (2) HK1068807A1 (de)
MX (1) MXPA04005382A (de)
WO (1) WO2003063770A2 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2001030847A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
EP1633387B1 (de) 2003-06-17 2012-02-22 Mannkind Corporation Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen
ES2350043T3 (es) * 2003-06-17 2011-01-17 Mannkind Corporation Composiciones para producir, incrementar y mantener las respuestas inmunes contra epítopos restringidos de mhc de clase i, con fines profilácticos o terapéuticos.
EP2481422A3 (de) * 2003-09-03 2013-04-03 Dendritherapeutics, Inc. Multiplex-Impfstoffe
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
US8354380B2 (en) * 2004-06-17 2013-01-15 Mannkind Corporation NY-ESO-1 peptide analogs
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
BRPI0514263B8 (pt) 2004-08-20 2021-05-25 Mannkind Corp método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
KR101306384B1 (ko) 2004-08-23 2013-09-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염
CA2589553C (en) * 2004-12-16 2014-02-18 Wake Forest University Health Sciences Use of flagellin in the immunotherapy of yersinia pestis
CA2592968A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
JP2008526764A (ja) * 2004-12-29 2008-07-24 マンカインド コーポレイション 免疫応答の誘導におけるｃｄ４＋細胞の回避方法
EP2351577A1 (de) 2004-12-29 2011-08-03 Mannkind Corporation Verfahren zum Auslösen, Beibehalten und Manipulieren von Immunantworten durch gezielte Verabreichung von Modifikationsmitteln der biologischen Reaktion in lymphatische Organe
CA2594224A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
CA2612518A1 (en) 2005-06-17 2006-12-28 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
US7999088B2 (en) 2005-06-17 2011-08-16 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
US7605227B2 (en) * 2005-06-17 2009-10-20 Mannkind Corporation Melanoma antigen peptide analogues
MX381952B (es) 2005-09-14 2025-03-13 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
JP5599975B2 (ja) 2006-02-22 2014-10-01 マンカインド コーポレイション ジケトピペラジン及び活性薬剤を含有する微粒子の製剤特性の改善方法
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
AU2007272785A1 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes
CN103736086A (zh) 2007-02-15 2014-04-23 曼康公司 用于增强t细胞应答的方法
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
JP2010528591A (ja) * 2007-05-23 2010-08-26 マンカインド コーポレイション マルチシストロン性ベクター及びそれらの設計方法
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2011163272A1 (en) 2010-06-21 2011-12-29 Mannkind Corporation Dry powder drug delivery system and methods
CA2721366C (en) 2008-04-17 2017-06-06 Elizabeth Ann Vasievich Stimulation of an immune response by enantiomers of cationic lipids
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101762089B1 (ko) 2008-06-13 2017-07-26 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
RU2011130796A (ru) 2008-12-24 2013-01-27 Онкотерапи Сайенс, Инк. Пептиды c1orf59 и содержащие их вакцины
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
MX2011013312A (es) 2009-06-12 2012-01-25 Mankind Corp Microparticulas de dicetopiperazina con areas de superficie especificas definidas.
WO2011008863A2 (en) * 2009-07-14 2011-01-20 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for hiv disease
EP2485750B1 (de) * 2009-10-05 2017-05-17 The Medical College of Wisconsin, Inc. Peptidbasierte myeloperoxidasehemmer und deren therapeutische verwendung
US20110274723A1 (en) 2009-10-23 2011-11-10 Mannkind Corporation Cancer immunotherapy and method of treatment
EP2496295A1 (de) 2009-11-03 2012-09-12 MannKind Corporation Vorrichtung und verfahren zur simulation von einatmungsanstrengungen
EP2506876B1 (de) 2009-12-02 2016-10-12 Imaginab, Inc. J591-minikörper und cys-diakörper zur adressierung des prostataspezifischen membranantigens (psma) und verfahren zu deren verwendung
SMT201700393T1 (it) * 2010-09-20 2017-09-07 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Recettori di cellule t antigene-specifici ed epitopi di cellule t
ES2625858T3 (es) 2011-04-01 2017-07-20 Mannkind Corporation Paquete de tipo blíster para cartuchos farmacéuticos
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
ES2777935T3 (es) 2012-06-15 2020-08-06 Pds Biotechnology Corp Composiciones de vacunas de lípidos catiónicos y procedimiento de uso
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送系统和方法
CA2885741C (en) 2012-09-21 2023-10-17 Frank Bedu-Addo Vaccine comprising r-dotap
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
MX369709B (es) 2013-03-15 2019-11-19 Univ Pennsylvania Vacunación mejorada contra tirosinasa.
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
EP3021834A1 (de) 2013-07-18 2016-05-25 MannKind Corporation Hitzestabile pharmazeutische trockenpulverzusammensetzungen und verfahren
EP3030294B1 (de) 2013-08-05 2020-10-07 MannKind Corporation Insufflationsvorrichtung
CN104761644A (zh) * 2014-01-03 2015-07-08 百奇生物科技（苏州）有限公司 大肠杆菌表达的融合蛋白mbp-mart-1及其制备和应用
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10816554B2 (en) 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
WO2015199617A1 (en) * 2014-06-24 2015-12-30 National University Of Singapore A monoclonal antibody with t-cell receptor-like specificity that targets epstein-barr infected human tumour cells based on their expression of ebna1
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
CN110035765B (zh) 2016-10-05 2024-04-02 Pds生物科技公司 新型hpv16非hla限制性t细胞疫苗、组合物及其使用方法
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
CN110950949B (zh) * 2018-09-26 2022-04-05 香雪生命科学技术（广东）有限公司 一种识别ssx2抗原的t细胞受体
CN115819555A (zh) * 2021-09-17 2023-03-21 香雪生命科学技术（广东）有限公司 一种识别ssx2的高亲和力tcr
US12030945B2 (en) 2022-10-25 2024-07-09 Seismic Therapeutic, Inc. Variant IgG Fc polypeptides and uses thereof
CN119506295A (zh) * 2025-01-21 2025-02-25 上海皓鸿生物医药科技有限公司 一种前列腺特异性膜抗原的制备方法

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613066A (en) * 1898-10-25 Bottle-stopper
US4439199A (en) * 1980-02-19 1984-03-27 Alza Corporation Method for administering immunopotentiator
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3937412A1 (de) 1989-11-10 1991-05-16 Hoechst Ag Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten
US5132213A (en) * 1986-10-02 1992-07-21 Massachusetts Institute Of Technology Method for producing proteins and polypeptides using ubiquitin fusions
US5093242A (en) * 1986-10-02 1992-03-03 Massachusetts Institute Of Technology Methods of generating desired amino-terminal residues in proteins
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
CA1341251C (en) * 1988-02-12 2001-06-12 David Bernard Boyle Pox virus vectors
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE184704T1 (de) * 1989-11-03 1999-10-15 Donald L Morton Nachweismethode für harnkarzinom-assoziierte antigene
SE466259B (sv) * 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US5451504A (en) 1991-07-29 1995-09-19 Serex, Inc. Method and device for detecting the presence of analyte in a sample
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
US5530096A (en) * 1992-12-22 1996-06-25 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
US5744316A (en) * 1992-12-22 1998-04-28 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5558995A (en) * 1993-01-22 1996-09-24 Ludwig Institute For Cancer Research Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
US5989565A (en) * 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
JPH08508252A (ja) * 1993-03-17 1996-09-03 アメリカ合衆国 小胞体シグナル配列ペプチドと少なくとも１個の他のペプチドをエンコードする核酸配列を含有する免疫原性キメラ、及びこのキメラのワクチン及び疾患の治療における使用
US5648226A (en) * 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
IT1266740B1 (it) * 1994-07-01 1997-01-14 Maria Paola Landini Materiale proteico ricombinante legante anticorpi contro il citomegalovirus umano, reagenti diagnostici derivati da tale
DE4423392A1 (de) 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Verfahren zur Identifizierung antigener Peptide
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
CN1180843C (zh) 1994-07-27 2004-12-22 昆士兰医学研究所 多表位疫苗
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
WO1997034613A1 (en) 1996-03-19 1997-09-25 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor
CA2252675A1 (en) 1996-04-26 1997-11-06 Rijksuniversiteit Te Leiden Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes
US5876972A (en) 1996-09-23 1999-03-02 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) * 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6287569B1 (en) * 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
DE69834494T2 (de) 1997-07-10 2007-03-01 Mannkind Corp., Valencia Vorrichtung zur induktion einer ctl-antwort
US7084239B1 (en) * 1997-10-08 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cancer peptides of NY-ESO-1/CAG-3
AU1387299A (en) * 1997-11-12 1999-05-31 Valentis, Inc. Expression plasmids for multiepitope nucleic acid-based vaccines
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
EP1064022A4 (de) 1998-03-13 2004-09-29 Epimmune Inc Hla-bindeproteine und deren verwendung
US6495136B1 (en) * 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
EP1131633A2 (de) 1998-11-16 2001-09-12 Board of Regents, The University of Texas System Hiv spezifische zelleninduktion
ATE274354T1 (de) 1999-01-08 2004-09-15 Wisconsin Alumni Res Found Impfungsmethode zur effizienten induktion der t- lymphozyten zytotoxischantwort
DK1157267T3 (en) 1999-03-03 2017-01-23 Olympus Corp Method for fluorescence binding assay
DE19909503A1 (de) 1999-03-04 2000-09-07 Boehringer Ingelheim Int Tumorassoziiertes Antigen
DE19919225A1 (de) 1999-04-28 2000-11-16 Boehringer Ingelheim Int Tumorassoziiertes Antigen
JP2003500037A (ja) 1999-05-26 2003-01-07 オレゴン ヘルス アンド サイエンス ユニバーシティー エピトープタンパク質のタグをもつ転移因子
DE19924199A1 (de) 1999-05-27 2000-11-30 Boehringer Ingelheim Int Tumorassoziiertes Antigen
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
DE19936563A1 (de) 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
DE60030450T2 (de) 1999-09-08 2007-08-30 Transgene S.A. Von MUC-1 abgeleitete Peptide
EP1214097B3 (de) 1999-09-16 2011-07-20 Eisai Inc. Für polyepitop-polypeptide kodierende nukleinsäuren
AU7917200A (en) 1999-09-30 2001-04-30 Institut Pasteur Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
EP1118860A1 (de) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Verfahren zur Auswahl und zur Herstellung von T-Zellen-Peptidepitopen sowie darauf basierten Impfstoffen
EP2311951A1 (de) 2000-01-28 2011-04-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Neuartige MHC Klasse II restringierte T-Zellepitope des Krebsantigens NY ESO-1
US6756044B1 (en) 2000-02-09 2004-06-29 Genvec, Inc. Antigenic complexes and methods
WO2001062917A1 (en) * 2000-02-22 2001-08-30 Ludwig Institute For Cancer Research Isolated genomic sequences which encode the ny-eso-1 cancer testis tumor antigen and uses thereof
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
AU2001257410B8 (en) 2000-04-28 2006-12-21 Mannkind Corporation Method of identifying and producing antigen peptides and use thereof as vaccines
DE10025521A1 (de) 2000-05-23 2001-12-06 Boehringer Ingelheim Int Tumor-assoziiertes Antigen B132
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
CU23235A1 (es) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
JP4179585B2 (ja) 2002-03-29 2008-11-12 ユニ・チャーム株式会社 印刷が施された生分解性プラスチックフィルム
CN1691964A (zh) 2002-09-06 2005-11-02 曼康公司 表位序列

Also Published As

Publication number Publication date
DK1453471T3 (da) 2011-03-28
US20040203051A1 (en) 2004-10-14
AU2008229722B2 (en) 2012-09-06
HK1075473A1 (en) 2005-12-16
US8252916B2 (en) 2012-08-28
EP1453471A2 (de) 2004-09-08
HK1068807A1 (en) 2005-05-06
EP2314712A1 (de) 2011-04-27
EP2314712B1 (de) 2014-01-08
US20030228634A1 (en) 2003-12-11
US20040132088A1 (en) 2004-07-08
DE60238864D1 (de) 2011-02-17
US7232682B2 (en) 2007-06-19
CA2469738A1 (en) 2003-08-07
US8637305B2 (en) 2014-01-28
WO2003063770A9 (en) 2004-06-17
WO2003063770A3 (en) 2004-04-01
CN101024842A (zh) 2007-08-29
MXPA04005382A (es) 2005-02-24
ES2358642T3 (es) 2011-05-12
EP1453471B1 (de) 2011-01-05
AU2008229722A1 (en) 2008-10-30
CN1612935A (zh) 2005-05-04
WO2003063770A2 (en) 2003-08-07
CN1313617C (zh) 2007-05-02
EP1453471A4 (de) 2006-11-29

Similar Documents

Publication Publication Date Title
ATE494387T1 (de) Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
WO2004044596A3 (en) Defect analyzer
DE3886265D1 (de) Anti-FR-900506-Stoffe-Antikörper und höchstempfindliches Enzym-Immunoassay-Verfahren.
DE3688246D1 (de) Kunstpolypeptide zum nachweis mykobakterieller infektionen.
TWI350914B (en) Systems and methods of inspecting a sample's surface and systems and methods for identifying a defect
ATE339687T1 (de) Immunologische verfahren, vorrichtungen und reagenzien
WO2004042795A3 (en) Method of preparing whole semiconductor wafer for analysis
ATE500496T1 (de) Verfahren für laser-anheftungs-mikrodissektion
DE69434406D1 (de) Extraktionsverfahren für Mikroorganismenantigene
NO932320D0 (no) Fremgangsmaate for paavisning av en analytt i en proeve og et utstyrsett for denne
DK0570489T3 (da) Leverstadium-specifikke peptidsekvenser af P.falciparum, der bærer epitoper, som er i stand til at stimulere T-lymfocytter
SE8802944D0 (sv) Materials for patch testing
EP1310794A3 (de) Antikörpertestverfahren und Antigenmikroarray
JP2001053136A (ja) ケース
Canelle et al. A proteomic approach to investigate potential biomarkers directed against membrane‐associated breast cancer proteins
DE69513649D1 (de) Verfahren zum nachweis der gegenwart einer mykobakterien-spezies und testsatz sowie antikörpes zur verwendung in diesem verfahren
EP0331514A3 (de) Prüfung der Deletion oder des Mangels an Protein von Duchenne-Muskeldystrophie
BRPI0418084A (pt) método para a preparação de suporte sólido pronto-para-usar para ensaio imunoabsorvente ligado a enzima (elisa) rápido
ATE326692T1 (de) Thermogravimetrische vorrichtung mit einem system zum öffnen eines probenhalters
SE8304190L (sv) Forfarande och reagens for immunologiska metningar
AU2562088A (en) Detection of tumor-associated markers in biological fluids
ES2063732T1 (es) Equipo y ensayo para determinar un antigeno/anticuerpo en una muestra.
DK161689D0 (da) Multi-immunoassay-system
Liebert et al. A method of membrane preparation for immunoassay
ATE79134T1 (de) Verfahren zur auslese von hybridomen, die spezifische antikoerper gegen unzugaengliche zelloberflaecheantigene erzeugen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties